Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea; BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, Kyungpook National University, Daegu, Republic of Korea.
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea; Lung Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
Gene. 2019 Jun 30;703:58-64. doi: 10.1016/j.gene.2019.04.013. Epub 2019 Apr 4.
This study was conducted to explore whether polymorphisms of glucose transporter 3 (GLUT3) gene affect the prognosis of patients with non-small cell lung cancer (NSCLC) after surgical resection. Four single nucleotide polymorphisms (SNPs) in GLUT3 were investigated in a total of 782 patients with NSCLC who underwent curative surgery. The association of the SNPs with overall survival (OS) and disease free survival (DFS) was analyzed. Among the four SNPs investigated, GLUT3 rs7309332C>T was significantly associated with OS and DFS in multivariate analyses. The SNP was associated with significantly worse OS (adjusted hazard ratio [aHR] = 1.62, 95% confidence interval [CI] = 1.04-2.53, P = 0.03, under recessive model), and worse DFS (aHR = 1.64, 95% CI = 1.18-2.29, P = 0.003, under recessive model). When stratified by tumor histology, the association between the GLUT3 rs7309332C>T and OS/DFS was not limited to either squamous cell carcinoma (SCC) or adenocarcinoma (AC), although the significant association remained only in AC for OS (P = 0.40 for SCC and P = 0.04 for OS) and only in SCC for DFS (P = 0.03 for SCC and P = 0.08 for OS). When AC patients were stratified according to EGFR mutation status, the SNP was significantly associated with DFS in patients with EGFR mutant tumors (aHR = 2.47, 95% CI = 1.15-5.30, P = 0.02, under recessive model), but not in those with EGFR wild-type tumors. This study suggests that genetic variation in GLUT3 may be useful in predicting survival of patients with early stage NSCLC.
这项研究旨在探讨葡萄糖转运蛋白 3 (GLUT3) 基因多态性是否影响接受根治性手术的非小细胞肺癌 (NSCLC) 患者的预后。在总共 782 名接受根治性手术的 NSCLC 患者中，研究人员调查了 GLUT3 中的 4 个单核苷酸多态性 (SNP)。分析了 SNPs 与总生存期 (OS) 和无病生存期 (DFS) 的关系。在研究的 4 个 SNP 中，GLUT3 rs7309332C>T 在多变量分析中与 OS 和 DFS 显著相关。该 SNP 与 OS 显著相关较差 (调整后的风险比[aHR] = 1.62，95%置信区间[CI] = 1.04-2.53，P = 0.03，在隐性模型下)，DFS 更差(aHR = 1.64，95%CI = 1.18-2.29，P = 0.003，在隐性模型下)。按肿瘤组织学分层时，GLUT3 rs7309332C>T 与 OS/DFS 的关联不仅限于鳞状细胞癌 (SCC) 或腺癌 (AC)，尽管 OS 中的显著关联仅在 AC 中存在 (SCC 为 P = 0.40，OS 为 P = 0.04)，DFS 仅在 SCC 中存在 (P = 0.03 SCC，OS 为 P = 0.08)。当根据 EGFR 突变状态对 AC 患者进行分层时，该 SNP 与 EGFR 突变肿瘤患者的 DFS 显著相关(aHR = 2.47，95%CI = 1.15-5.30，P = 0.02，在隐性模型下)，但与 EGFR 野生型肿瘤患者无关。这项研究表明，GLUT3 中的遗传变异可能有助于预测早期 NSCLC 患者的生存情况。
